Bayer, Curadev Enter ‘STING’ Pact Exploring Inflammatory Disease
Duo Using Curadev’s Stimulator Of Interferon Genes Antagonist Platform
Bayer and Curadev entered a research collaboration and license agreement to develop novel STING antagonists targeting inflammatory disease.
You may also be interested in...
Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.
The Japanese pharma, continuing to bolster its pipeline after buying Shire, is partnering with Skyhawk in neurodegenerative diseases under another new deal. Also, Purdue cites shifting business priorities for a decision to end Eisai collaboration on sleep disorder drug.
The submission of more trial data from Roche has prompted the US FDA to extend by three months its decision on whether to approve risdiplam for spinal muscular atrophy.